{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:51:47Z","timestamp":1791924707454,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bone.2020.115411","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:22:05Z","timestamp":1589152925000},"page":"115411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["History of alendronate"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8808-260X","authenticated-orcid":false,"given":"Steven R.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur C.","family":"Santora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Graham G.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bone.2020.115411_bb0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif. Tissue Int."},{"issue":"6","key":"10.1016\/j.bone.2020.115411_bb0010","first-page":"1399","article-title":"The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women","volume":"76","author":"Harris","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bone.2020.115411_bb0015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am. J. Med."},{"issue":"22","key":"10.1016\/j.bone.2020.115411_bb0020","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bone.2020.115411_bb0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","article-title":"Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy","volume":"95","author":"Harris","year":"1993","journal-title":"Am. J. Med."},{"issue":"8837","key":"10.1016\/j.bone.2020.115411_bb0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0140-6736(93)92555-8","article-title":"Bone-density at various sites for prediction of hip-fractures","volume":"341","author":"Cummings","year":"1993","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2020.115411_bb0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","article-title":"Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group","volume":"14","author":"Black","year":"1999","journal-title":"J. Bone Miner. Res."},{"issue":"9041","key":"10.1016\/j.bone.2020.115411_bb0040","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bone.2020.115411_bb0045","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.bone.2020.115411_bb0050","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2020.115411_bb0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos. Int."},{"issue":"24","key":"10.1016\/j.bone.2020.115411_bb0060","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.bone.2020.115411_bb0065","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115411_bb0070","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"22","key":"10.1016\/j.bone.2020.115411_bb0075","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115411_bb0080","series-title":"Dietary Reference Intakes for Calcium and Vitamin D","article-title":"The National Academies Collection: reports funded by National Institutes of Health","author":"Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D, Calcium","year":"2011"},{"issue":"1","key":"10.1016\/j.bone.2020.115411_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"7","key":"10.1016\/j.bone.2020.115411_bb0090","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115411_bb0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2020.115411_bb0100","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1023\/A:1018894827961","article-title":"Esophageal irritation due to alendronate sodium tablets: possible mechanisms","volume":"43","author":"Peter","year":"1998","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.bone.2020.115411_bb0105","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"issue":"5 Suppl","key":"10.1016\/j.bone.2020.115411_bb0110","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.bone.2020.115411_bb0115","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"Neviaser","year":"2008","journal-title":"J. Orthop. Trauma"},{"issue":"3","key":"10.1016\/j.bone.2020.115411_bb0120","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00198-017-4345-0","article-title":"Hip fracture trends in the United States, 2002 to 2015","volume":"29","author":"Michael Lewiecki","year":"2018","journal-title":"Osteoporos. Int."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220301915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:51:21Z","timestamp":1757613081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220301915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":24,"alternative-id":["S8756328220301915"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115411","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"History of alendronate","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115411"}}